Our Life Sciences & Technology Venture Finance team collaborates with companies to structure and deliver scaled, flexible, and capital-efficient financing solutions.
Our minimally dilutive capital serves as an adjunct to equity for financing acquisitions, enhancing a product launch, or advancing development-stage programs. We specialize in senior secured term loans ranging from $5 million to $200 million+ and can combine these with asset based lines of credit for commercial-stage companies to optimize cost of capital.
We have extensive experience working with emerging, commercial stage medical device, healthcare information technology, research tools, and diagnostics companies, and development-stage biotech and pharma companies. In technology, our venture debt experts work with private and public commercial stage companies in the enterprise software, networking, and hardware industries.
*Based on sourcing deal count/volume between September 16, 2008 – September 30, 2022.
Reach out to learn more about how Life Sciences & Technology Venture Finance can serve your specific needs.
Have a question?
Our team is growing. So can you.
The conversation starts here.